Autoimmune hepatitis induced by bosentan in a patient with pulmonary arterial hypertension (RCD code: II-1A.1; VIII)

SUMMARY

Endothelin receptor antagonist (ERA) therapy-induced increase in liver transaminases in patients with pulmonary arterial hypertension (PAH) is an adverse effect of bosentan which is not fully understood. A 62-year-old female with a 1.5-year history of progressively worsening dyspnoea was diagnosed with idiopathic PAH (IPAH). After 2 months of PAH treatment with bosentan, levels of liver transaminases were elevated and autoimmune hepatitis was diagnosed. This clinical case demonstrates the challenge of diagnosing autoimmune hepatitis induced by ERA therapy in clinical practice. A thorough understanding of the pathogenesis and clinical presentation of autoimmune hepatitis, as well as the possibility to perform specific investigations with multiple serological markers are crucial for establishing the correct diagnosis. JRCD 2019; 4 (4): 101-105.